Amping Up Effort: Effects of d-Amphetamine on Human Effort-Based Decision-Making
- 1Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois 60637,
- 2Department of Psychology, Vanderbilt University, Nashville, Tennessee 37240, and
- 3Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tennessee 37212
-
Author contributions: M.C.W., M.T.T., D.H.Z., and H.d.W. designed research; M.C.W. performed research; M.C.W., M.T.T., and L.M.M. analyzed data; M.C.W., M.T.T., L.M.M., D.H.Z., and H.d.W. wrote the paper.
Abstract
Animal studies suggest the neurotransmitter dopamine (DA) plays an important role in decision-making. In rats, DA depletion decreases tolerance for effort and probability costs, while drugs enhancing DA increase tolerance for these costs. However, data regarding the effect of DA manipulations on effort and probability costs in humans remain scarce. The current study examined acute effects of d-amphetamine, an indirect DA agonist, on willingness of healthy human volunteers to exert effort for monetary rewards at varying levels of reward value and reward probability. Based on preclinical research, we predicted amphetamine would increase exertion of effort, particularly when reward probability was low. Over three sessions, 17 healthy normal adults received placebo, d-amphetamine 10 mg, and 20 mg under counterbalanced double-blind conditions and completed the Effort Expenditure for Rewards Task. Consistent with predictions, amphetamine enhanced willingness to exert effort, particularly when reward probability was lower. Amphetamine did not alter effects of reward magnitude on willingness to exert effort. Amphetamine sped task performance, but its psychomotor effects were not strongly related to its effects on decision-making. This is the first demonstration in humans that dopaminergic manipulations alter willingness to exert effort for rewards. These findings help elucidate neurochemical substrates of choice, with implications for neuropsychiatric diseases characterized by dopaminergic dysfunction and motivational deficits.
- Received August 26, 2011.
- Revision received September 28, 2011.
- Accepted September 30, 2011.
- Copyright © 2011 the authors 0270-6474/11/3116597-06$15.00/0





